The extraordinary general meeting in Soft-Ox Solutions AS was held Wednesday 27
March 2024. 
All agenda items were approved in line with the proposals in the extraordinary
general meeting notice with the amendments set out in the notices from the
Company earlier today.
See separate press release with key information relating to the subsequent
offering, with the following key information:

Last day including right: 27 March 2024
Ex-date: 2 April 2024
Record date: 3 April 2024
Date of approval: 27 April 2024
Maximum number of new shares: 125,000,000
Subscription price: NOK 0,2

The Company will provide update on the subsequent offering in a separate notice.
The minutes from the Extraordinary General Meeting in Norwegian and English are
attached.

For any questions or interview requests, please contact: 
Geir Almås, Chair of SoftOx Solutions AS 
Mail: ir@soft-ox.com 
Phone: Geir Almås: (+47) 977 59 071 

About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx
Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly
effective antimicrobial solution for use in biofilm, viral and antimicrobial
resistant infections. The patent-protected technology is based on extensive
research and development in partnership with leading Nordic research institutes.
For more information on SoftOx, visit www.soft-ox.com